Response rate in relapsed/refractory MCL patients receiving idelalisib
| Category . | All patients (N = 40) . | Receiving <150 mg bid* (n = 24) . | Receiving ≥150 mg qd† (n = 16) . |
|---|---|---|---|
| ORR | 16 (40) | 5 (21) | 11 (69) |
| CR | 2 (5) | 0 | 2 (12.5) |
| PR | 14 (35) | 5 (21) | 9 (56.3) |
| SD | 19 (47.5) | 15 (62.5) | 4 (25) |
| PD | 4 (10) | 4 (16.7) | 0 |
| NE | 1 (2.5) | 0 | 1/16 (6.3) |
| Category . | All patients (N = 40) . | Receiving <150 mg bid* (n = 24) . | Receiving ≥150 mg qd† (n = 16) . |
|---|---|---|---|
| ORR | 16 (40) | 5 (21) | 11 (69) |
| CR | 2 (5) | 0 | 2 (12.5) |
| PR | 14 (35) | 5 (21) | 9 (56.3) |
| SD | 19 (47.5) | 15 (62.5) | 4 (25) |
| PD | 4 (10) | 4 (16.7) | 0 |
| NE | 1 (2.5) | 0 | 1/16 (6.3) |
Data are presented as number (%) of patients.
bid, twice daily; CR, complete response; NE, not evaluable; PR, partial response; qd, daily.
Dose cohorts include 150 mg daily, 150 mg twice daily × 21 days, 50 mg twice daily, and 100 mg twice daily.
Dose cohorts include 300 mg daily, 150 mg twice daily, 200 mg twice daily, and 350 mg twice daily.